Blood Glucose Control in Type 2 Diabetes
Lifestyle intervention is the foundation of all diabetes care, and metformin should be initiated immediately if HbA1c ≥ 7.0%, with treatment intensification guided by cardiovascular and renal comorbidities rather than glucose levels alone. 1
Initial Treatment Strategy
Start metformin at diagnosis unless contraindicated, titrating to 2000 mg daily (1000 mg twice daily) for maximal glucose-lowering effect. 1 Begin at 500 mg once or twice daily with meals to minimize gastrointestinal side effects, increasing by 500 mg weekly. 1 Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m². 1
Initiate lifestyle modifications concurrently: aim for 5–7% weight loss and at least 150 minutes per week of moderate-intensity physical activity. 1, 2 These interventions can reduce HbA1c by 0.4–1.0% and improve cardiovascular risk factors. 3
Glycemic Targets
For most nonpregnant adults with type 2 diabetes, target HbA1c < 7.0% to reduce microvascular and macrovascular complications. 1, 3
More stringent targets (HbA1c < 6.5%) are appropriate for patients with short disease duration, long life expectancy, no complications, and no significant cardiovascular disease—provided hypoglycemia risk is low. 1
Less stringent targets (HbA1c < 8.0%) are indicated for patients with: 1
- History of severe hypoglycemia
- Limited life expectancy (< 10 years)
- Advanced microvascular or macrovascular complications
- Extensive comorbid conditions
- Long-standing diabetes where goals are difficult to achieve despite comprehensive treatment
Treatment Escalation Algorithm
When Metformin Monotherapy Fails (HbA1c ≥ 7.0% after 3 months)
Add a second agent based on comorbidities, NOT simply glucose levels: 4, 3
If cardiovascular disease, heart failure, or chronic kidney disease is present:
- Add an SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin) OR a GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide) FIRST, regardless of HbA1c level. 4, 3
- SGLT2 inhibitors reduce heart failure hospitalizations by 18–25%, cardiovascular events by 12–26%, and CKD progression by 24–39%. 4, 3
- GLP-1 receptor agonists reduce major adverse cardiovascular events by 26–29% and stroke risk by 12–26%. 4, 3
If no cardiovascular or renal disease:
- Dual therapy options include: DPP-4 inhibitors, sulfonylureas, α-glucosidase inhibitors, thiazolidinediones, SGLT2 inhibitors, GLP-1 receptor agonists, or insulin. 1
- Preferred agents are GLP-1 receptor agonists or SGLT2 inhibitors due to weight loss benefits and low hypoglycemia risk. 4, 3
When Dual Therapy Fails (HbA1c ≥ 7.0% after 3 months)
Add a third oral agent or initiate basal insulin. 1
Triple therapy combinations may include: 1
- Metformin + SGLT2 inhibitor + GLP-1 receptor agonist (preferred for cardiovascular/renal protection)
- Metformin + DPP-4 inhibitor + sulfonylurea
- Metformin + thiazolidinedione + sulfonylurea
If triple therapy fails, proceed to basal insulin: 1
- Start basal insulin (NPH or long-acting analog) at 10 units once daily at bedtime OR 0.1–0.2 units/kg body weight. 1
- Titrate by 2–4 units every 3 days until fasting glucose reaches 80–130 mg/dL without hypoglycemia. 1
- Continue metformin when adding insulin—it reduces insulin requirements, prevents weight gain, and provides cardiovascular benefit. 1
Severe Hyperglycemia (HbA1c ≥ 9–10% or glucose ≥ 300 mg/dL)
Initiate combination therapy with metformin PLUS basal insulin immediately at diagnosis. 5, 3 Monotherapy cannot achieve adequate control at this severity. 5
If symptomatic hyperglycemia, ketosis, or catabolic features are present, start insulin without delay. 1, 5
Insulin Intensification
If fasting glucose is controlled but postprandial glucose remains > 180 mg/dL, add prandial insulin: 1
- Start with 4 units of rapid-acting insulin (lispro, aspart, or glulisine) before the largest meal OR 10% of basal dose. 1
- Titrate by 1–2 units every 3 days based on 2-hour postprandial readings. 1
When initiating multiple daily insulin injections, discontinue sulfonylureas to avoid severe hypoglycemia. 1
Monitoring and Follow-Up
Reassess HbA1c every 3 months until target is achieved, then every 6 months once stable. 1 This is the longest acceptable interval before intensifying therapy—therapeutic inertia increases complication risk. 1
Monitor renal function (eGFR) at baseline and annually: 1
- Reduce metformin dose when eGFR 45–59 mL/min/1.73 m²
- Halve metformin dose when eGFR 30–44 mL/min/1.73 m²
- Discontinue metformin when eGFR < 30 mL/min/1.73 m²
Check vitamin B12 levels periodically in patients on long-term metformin, especially if anemia or peripheral neuropathy develops. 1
Comprehensive Cardiovascular Risk Management
Blood glucose control is only one component—aggressively manage: 1
- Blood pressure: target < 130/80 mmHg 1
- LDL cholesterol: < 2.6 mmol/L (without ASCVD) or < 1.8 mmol/L (with ASCVD) 1
- BMI: target < 24 kg/m² 1
- Aspirin, statins, and ACE inhibitors for cardiovascular risk reduction 2
Critical Pitfalls to Avoid
Do not delay treatment intensification beyond 3 months if HbA1c remains above target—prolonged hyperglycemia increases micro- and macrovascular complications. 1
Do not discontinue metformin when adding other agents unless contraindicated—it remains foundational therapy throughout all treatment stages. 1, 4
Do not use sulfonylureas as first-line agents in older adults or those with renal impairment—they carry a 7-fold higher risk of severe hypoglycemia compared to metformin. 1
Do not combine GLP-1 receptor agonists with DPP-4 inhibitors—no additional glucose-lowering benefit has been demonstrated. 1
Do not target HbA1c < 6.5% in elderly patients or those with limited life expectancy—this increases hypoglycemia risk without proven mortality benefit. 1
Do not overlook cardiovascular and renal comorbidities when selecting second-line agents—SGLT2 inhibitors and GLP-1 receptor agonists provide organ protection independent of glucose lowering. 4, 3